Engineers Gate Manager LP Vericel Corp Transaction History

Engineers Gate Manager LP

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$41.71 - $52.9 $232,241 - $294,547	5,568 New	5,568 $255,000
Q4 2023 Feb 14, 2024	BUY	$30.85 - $37.09 $440,044 - $529,051	14,264 Added 144.93%	24,106 $858,000
Q3 2023 Nov 14, 2023	BUY	$31.69 - $39.25 $311,892 - $386,298	9,842 New	9,842 $329,000
Q1 2023 May 15, 2023	BUY	$23.85 - $31.34 $205,229 - $269,680	8,605 New	8,605 $252,000
Q2 2022 Aug 15, 2022	SELL	$22.88 - $39.45 $132,658 - $228,731	-5,798 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$31.69 - $43.29 $183,738 - $250,995	5,798 New	5,798 $222,000
Q3 2021 Nov 15, 2021	SELL	$46.35 - $59.75 $592,631 - $763,963	-12,786 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$47.2 - $67.81 $603,499 - $867,018	12,786 New	12,786 $671,000
Q1 2021 May 17, 2021	SELL	$30.93 - $59.48 $311,774 - $599,558	-10,080 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$18.53 - $31.5 $186,782 - $317,520	10,080 New	10,080 $311,000
Q1 2020 May 15, 2020	SELL	$7.25 - $19.22 $115,927 - $307,327	-15,990 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$13.77 - $19.2 $220,182 - $307,008	15,990 New	15,990 $278,000

276

48.5M

91.8K

23.2K

Ticker VCEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 47,178,000
Market Cap $2.61B
Description
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in the United States. The company markets autologous cell therapy products comprising MACI, an autologous cellularized scaffold product for t...

Get notified when there are updates to the investment portfolio of Engineers Gate Manager LP, based on Form 13F filings with the SEC.

Stay updated on Engineers Gate Manager LP with notifications on news.